EGFR and non-small cell lung carcinoma: In light of the above, the ‘LUNGFUL’ observational study was designed to assess the frequency of T790M acquired resistance and predictors of its presence, in patients with EGFR-mutated locally advanced or metastatic NSCLC who have progressed in the first-line EGFR-TKI treatment setting with first- or second-generation TKIs and have undergone molecular testing using the FDA-approved cobas®EGFR Mutation Test v2 in tissue and/or plasma biopsy.